☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Associated
BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia
March 15, 2021
Jazz Pharmaceuticals' Xywav (calcium- magnesium- potassium- and sodium oxybates) Receives the US FDA's Approval for Cataplexy or E...
July 22, 2020
Angion Commences P-II Study of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia in Brazil
July 8, 2020
Zogenix's Fintepla (fenfluramine) Receives the US FDA's Approval for the Treatment of Seizures Associated with Dravet Syndrome
June 26, 2020
Theravance Reports First Patient Dosing in a P-II Study of TD-0903 for Hospitalized Patients with Acute Lung Injury Associated wit...
June 25, 2020
GSK to Evaluate Otilimab for Treating Pulmonary Disease Associated with COVID-19
May 8, 2020
89bio Commences P-III Study of Pegozafermin for Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH)
March 13, 2024
Madrigal Pharmaceuticals Reports the EMA’s Validation for the MAA of Resmetirom to Treat NASH/MASH with Liver Fibrosis
March 6, 2024
Boehringer Ingelheim Reports Results from the P-II Study of Survodutide for the Treatment of Metabolic Dysfunction-Associated Stea...
February 27, 2024
AM-Pharma Commences P-II Study Evaluating Ilofotase Alfa for Cardiac Surgery-Associated Renal Damage
January 16, 2024
SpringWorks Therapeutics Reports the Results for Mirdametinib in P-IIb Trial to Treat Neurofibromatosis Type 1-Associated Plexifor...
November 17, 2023
Astella’s Veoza Received Positive Opinion from EU’s CHMP for the treatment of VMS associated with Menopause
October 16, 2023
Load more...
Back to Home
Modal title
×
Modal body text goes here.